Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

Dow, S&P 500, and Nasdaq futures are rising in premarket trading Wednesday as the stock market braces for minutes from the Fed's monetary policy meeting.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...